한글목차

선천성 횡격막 탈장 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 46억 9,000만 달러에서 2026년에는 50억 1,000만 달러로, CAGR 6.9%로 확대될 것으로 예상됩니다. 지금까지의 성장 요인으로는 제한된 치료 옵션, 높은 신생아 사망률, 선천성 횡격막 탈장에 대한 낮은 인식, 의료 인프라의 단편화, 표준화된 치료 프로토콜의 부족 등을 꼽을 수 있습니다.

선천성 횡격막 탈장 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 68억 1,000만 달러에 달하고, CAGR은 8.0%가 될 전망입니다. 예측 기간의 성장 요인으로는 정밀의료의 발전, 신생아 치료에 대한 투자 증가, 조기 개입에 대한 인식 개선, 약물전달 기술의 발전, 신흥 지역의 의료 인프라 확충 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 첨단 신생아 치료 약물, 최소침습적 치료 접근법, 개별화된 약물 처방, 조기 진단 및 중재 요법, 다각적 증상 관리 등이 있습니다.

선천성 횡격막 탈장(CDH) 치료제 시장의 성장은 선천성 기형 발생률 증가가 견인할 것으로 예상됩니다. 선천성 기형이란 출생 시 존재하는 구조적 또는 기능적 이상으로 신생아의 전반적인 건강 상태와 발달에 영향을 미칠 수 있는 질환을 말합니다. 선천성 횡격막 탈장의 치료법에는 산전 검사, 유전 상담, 그리고 CDH와 관련된 선천성 기형의 발생을 줄이고 조기 개입과 개별화된 치료를 가능하게 하는 표적 치료법이 포함됩니다. 이를 통해 영향을 받는 개인의 전반적인 건강 상태와 삶의 질을 향상시킬 수 있습니다. 예를 들어, 2023년 3월 미국에 본부를 둔 정부 간 기구인 세계보건기구(WHO)가 발표한 자료에 따르면, 연간 약 800만 명의 영아가 선천성 기형을 가지고 태어나는데, 10건 중 9건이 중저소득 국가에서 발생한다고 합니다. 또한, 선천성 질환으로 인해 전 세계적으로 연간 약 24만 명의 신생아가 출생 후 28일 이내에 사망하는 것으로 추정되고 있습니다. 따라서 선천성 기형의 증가율이 선천성 횡격막 탈장 치료제 시장을 주도하고 있습니다.

제약 분야의 임상시험 증가는 향후 선천성 횡격막 탈장 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 의약품 임상시험은 새로운 약품이나 치료법의 안전성 및 유효성을 평가하기 위해 사람을 대상으로 하는 조사입니다. 임상시험의 증가는 혁신적이고 효과적인 치료법에 대한 수요 증가에 의해 촉진되고 있습니다. 선천성 횡격막 탈장 치료제는 임상시험을 통해 선천성 횡격막 탈장 신생아의 치료 결과 개선에 대한 안전성과 유효성을 평가합니다. 예를 들어, 영국에 기반을 둔 단체인 영국제약산업협회(ABPI)에 따르면, 2024년 12월 기준 영국에서 시작된 총 임상시험 건수는 2022년 411건에서 2023년 426건으로 증가했습니다. 따라서 의약품 분야의 임상시험 증가가 선천성 횡격막 탈장 치료제 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Congenital diaphragmatic hernia (CDH) is a rare condition in which there is a hole in the diaphragm, the muscle that separates the chest from the abdomen. Drugs for congenital diaphragmatic hernia (CDH) are medications used to treat the condition, helping to reduce disease severity and manage the symptoms and complications associated with it.

The main types of drugs for congenital diaphragmatic hernia are posterolateral Bochdalek hernia, anterior Morgagni hernia, and hiatal hernia. Posterolateral Bochdalek hernia is a type of CDH in which an opening or defect in the back part of the diaphragm allows abdominal organs to move into the chest cavity. Treatments include options such as extracorporeal membrane oxygenation and others, applied through various diagnostic approaches, including prenatal and postnatal. These drugs are used by end users such as hospitals, home care providers, specialty clinics, and others.

Tariffs have affected the congenital diaphragmatic hernia drugs market by increasing the cost of imported active pharmaceutical ingredients and advanced neonatal care equipment, leading to higher treatment costs. The impact is most pronounced in regions relying heavily on imports, such as Asia-Pacific and parts of Europe, while hospitals and specialty clinics face operational challenges. However, tariffs are also driving local manufacturing initiatives and innovation in cost-efficient drug formulations, which could provide long-term benefits to the market.

The congenital diaphragmatic hernia drugs market research report is one of a series of new reports from The Business Research Company that provides congenital diaphragmatic hernia drugs market statistics, including congenital diaphragmatic hernia drugs industry global market size, regional shares, competitors with a congenital diaphragmatic hernia drugs market share, detailed congenital diaphragmatic hernia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the congenital diaphragmatic hernia drugs industry. This congenital diaphragmatic hernia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital diaphragmatic hernia drugs market size has grown strongly in recent years. It will grow from $4.69 billion in 2025 to $5.01 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to limited therapeutic options, high neonatal mortality rates, low awareness of congenital diaphragmatic hernia, fragmented healthcare infrastructure, lack of standardized treatment protocols.

The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growth in precision medicine, increasing investment in neonatal care, rising awareness of early intervention, advancements in drug delivery technologies, expansion of healthcare infrastructure in emerging regions. Major trends in the forecast period include advanced neonatal care medications, minimally invasive treatment approaches, personalized drug formulations, early diagnosis and intervention therapies, multi-modal symptom management.

The rising rate of birth defects is expected to drive the growth of the congenital diaphragmatic hernia (CDH) drug market. Birth defects are structural or functional abnormalities present at birth that can impact a newborn's overall health and development. Treatments for congenital diaphragmatic hernia include prenatal screening, genetic counseling, and targeted therapies that reduce the occurrence of birth defects associated with CDH and enable early intervention and personalized care, thereby improving the overall well-being and quality of life of affected individuals. For instance, in March 2023, according to the World Health Organization (WHO), a US-based intergovernmental organization, approximately 8 million infants are born with birth defects annually, with low- and middle-income countries accounting for nine out of ten major cases. Additionally, an estimated 240,000 newborns die worldwide each year within 28 days of birth due to congenital disorders. Therefore, the rising rate of birth defects is driving the congenital diaphragmatic hernia drug market.

The increasing number of clinical trials in pharmaceuticals is expected to drive the growth of the congenital diaphragmatic hernia drug market going forward. Clinical trials in pharmaceuticals are research studies that evaluate new drugs or treatments in humans to determine their safety and effectiveness. The rise in clinical trials is driven by the growing need for innovative and more effective therapies. Congenital diaphragmatic hernia drugs are tested in clinical trials to assess their safety and effectiveness in improving outcomes for affected newborns. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the total number of clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Therefore, the rise in clinical trials in pharmaceuticals is driving the growth of the congenital diaphragmatic hernia drug market.

In May 2023, Juno Pharmaceuticals, a Canada-based pharmaceutical company, acquired Omega Laboratories Inc. for an undisclosed amount. This acquisition positions Juno as the largest specialty generic injectable company in Canada, enhancing its capacity to supply essential drugs in the sector. The merger aims to improve access to injectable medications, significantly strengthening Juno's presence in the specialty pharmaceutical market. Omega Laboratories Inc. is a US-based drug testing laboratory that produces medications supporting the management of conditions related to congenital diaphragmatic hernia.

Major companies operating in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Bayer AG, Mallinckrodt Pharmaceuticals, Boehringer Ingelheim International GmbH, AbbVie Inc., Sanofi SA, Johnson & Johnson, United Therapeutics Corporation, Bristol-Myers Squibb Company, Aurobindo Pharma Ltd, Cipla Inc., Lupin Ltd., Zydus Lifesciences Ltd., Fresenius Kabi.

North America was the largest region in the congenital diaphragmatic hernia drugs market in 2025. The regions covered in the congenital diaphragmatic hernia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the congenital diaphragmatic hernia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital diaphragmatic hernia drugs market consists of revenues earned by entities by providing surgical treatments and medical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital diaphragmatic hernia drug market also includes sales of pain management medications, antibiotics, vasoactive agents, dobutamine and milrinone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Diaphragmatic Hernia Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses congenital diaphragmatic hernia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congenital diaphragmatic hernia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The congenital diaphragmatic hernia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Posterolateral Bochdalek Hernia; Anterior Morgagni Hernia; Hiatal Hernia
• 2) By Treatment: Extracorporeal Membrane Oxygenation; Other Treatments
• 3) By Diagnosis: Prenatal; Postnatal
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Posterolateral Bochdalek Hernia: Surgical Interventions; Medications for Symptoms
• 2) By Anterior Morgagni Hernia: Medications for Symptoms
• 3) By Hiatal Hernia: Surgical Interventions; Medications
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; GlaxoSmithKline plc; Novartis AG; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Viatris Inc.; Bayer AG; Mallinckrodt Pharmaceuticals; Boehringer Ingelheim International GmbH; AbbVie Inc.; Sanofi SA; Johnson & Johnson; United Therapeutics Corporation; Bristol-Myers Squibb Company; Aurobindo Pharma Ltd; Cipla Inc.; Lupin Ltd.; Zydus Lifesciences Ltd.; Fresenius Kabi.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Congenital Diaphragmatic Hernia Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Congenital Diaphragmatic Hernia Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Congenital Diaphragmatic Hernia Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Congenital Diaphragmatic Hernia Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Advanced Neonatal Care Medications
  • 4.2.2 Minimally Invasive Treatment Approaches
  • 4.2.3 Personalized Drug Formulations
  • 4.2.4 Early Diagnosis And Intervention Therapies
  • 4.2.5 Multi-Modal Symptom Management

5. Congenital Diaphragmatic Hernia Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Neonatal Care Centers
• 5.4 Homecare Providers
• 5.5 Research Institutions

6. Congenital Diaphragmatic Hernia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Congenital Diaphragmatic Hernia Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Congenital Diaphragmatic Hernia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Congenital Diaphragmatic Hernia Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Congenital Diaphragmatic Hernia Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Congenital Diaphragmatic Hernia Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Congenital Diaphragmatic Hernia Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Congenital Diaphragmatic Hernia Drugs Market Segmentation

• 9.1. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia
• 9.2. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Extracorporeal Membrane Oxygenation, Other Treatments
• 9.3. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prenatal, Postnatal
• 9.4. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.5. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Posterolateral Bochdalek Hernia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgical Interventions, Medications for Symptoms
• 9.6. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Anterior Morgagni Hernia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Medications for Symptoms
• 9.7. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Hiatal Hernia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgical Interventions, Medications

10. Congenital Diaphragmatic Hernia Drugs Market Regional And Country Analysis

• 10.1. Global Congenital Diaphragmatic Hernia Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Congenital Diaphragmatic Hernia Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market

• 11.1. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Congenital Diaphragmatic Hernia Drugs Market

• 12.1. China Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Congenital Diaphragmatic Hernia Drugs Market

• 13.1. India Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Congenital Diaphragmatic Hernia Drugs Market

• 14.1. Japan Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Congenital Diaphragmatic Hernia Drugs Market

• 15.1. Australia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Congenital Diaphragmatic Hernia Drugs Market

• 16.1. Indonesia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Congenital Diaphragmatic Hernia Drugs Market

• 17.1. South Korea Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Congenital Diaphragmatic Hernia Drugs Market

• 18.1. Taiwan Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Congenital Diaphragmatic Hernia Drugs Market

• 19.1. South East Asia Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Congenital Diaphragmatic Hernia Drugs Market

• 20.1. Western Europe Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Congenital Diaphragmatic Hernia Drugs Market

• 21.1. UK Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Congenital Diaphragmatic Hernia Drugs Market

• 22.1. Germany Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Congenital Diaphragmatic Hernia Drugs Market

• 23.1. France Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Congenital Diaphragmatic Hernia Drugs Market

• 24.1. Italy Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Congenital Diaphragmatic Hernia Drugs Market

• 25.1. Spain Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market

• 26.1. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Congenital Diaphragmatic Hernia Drugs Market

• 27.1. Russia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Congenital Diaphragmatic Hernia Drugs Market

• 28.1. North America Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Congenital Diaphragmatic Hernia Drugs Market

• 29.1. USA Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Congenital Diaphragmatic Hernia Drugs Market

• 30.1. Canada Congenital Diaphragmatic Hernia Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Congenital Diaphragmatic Hernia Drugs Market

• 31.1. South America Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Congenital Diaphragmatic Hernia Drugs Market

• 32.1. Brazil Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Congenital Diaphragmatic Hernia Drugs Market

• 33.1. Middle East Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Congenital Diaphragmatic Hernia Drugs Market

• 34.1. Africa Congenital Diaphragmatic Hernia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Congenital Diaphragmatic Hernia Drugs Market Regulatory and Investment Landscape

36. Congenital Diaphragmatic Hernia Drugs Market Competitive Landscape And Company Profiles

• 36.1. Congenital Diaphragmatic Hernia Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Congenital Diaphragmatic Hernia Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Congenital Diaphragmatic Hernia Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Congenital Diaphragmatic Hernia Drugs Market Other Major And Innovative Companies

• Teva Pharmaceutical Industries Ltd., Viatris Inc., Bayer AG, Mallinckrodt Pharmaceuticals, Boehringer Ingelheim International GmbH, AbbVie Inc., Sanofi SA, Johnson & Johnson, United Therapeutics Corporation, Bristol-Myers Squibb Company, Aurobindo Pharma Ltd, Cipla Inc., Lupin Ltd., Zydus Lifesciences Ltd., Fresenius Kabi

38. Global Congenital Diaphragmatic Hernia Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Congenital Diaphragmatic Hernia Drugs Market

40. Congenital Diaphragmatic Hernia Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Congenital Diaphragmatic Hernia Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Congenital Diaphragmatic Hernia Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Congenital Diaphragmatic Hernia Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer